ArticleCureus2026
Secondary Cutaneous Plasmacytoma as a Manifestation of Extramedullary Multiple Myeloma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a clonal plasma cell malignancy that typically remains confined to the bone marrow; however, a subset of patients develops extramedullary disease (EMD), which is associated with advanced disease stage and poor prognosis. Cutaneous involvement represents a particularly rare manifestation of EMD, accounting for a small proportion of cases and usually indicating aggressive systemic progression. Due to its infrequency and heterogeneous clinical presentation, cutaneous plasmacytoma is often underrecognized, leading to diagnostic delays. We report the case of a 54-year-old Mexican woman with a history of MM who developed a painful, violaceous, ulcerated plaque on the left upper extremity following interruption of systemic therapy due to treatment-related neuropathy. Histopathological examination revealed a dense dermal infiltrate of mature plasma cells characterized by eccentric nuclei, basophilic cytoplasm, and clock-face chromatin. Immunohistochemical analysis demonstrated strong positivity for CD138 and kappa light-chain restriction, confirming the diagnosis of secondary cutaneous plasmacytoma associated with MM. This case highlights the importance of maintaining a high index of suspicion for atypical cutaneous lesions in patients with MM, particularly in the context of disease relapse or treatment interruption. Prompt skin biopsy with immunophenotypic confirmation is essential for accurate diagnosis and timely management. Cutaneous involvement reflects aggressive disease biology and underscores the limitations of localized therapies, emphasizing the need for systemic treatment strategies. Increased awareness and reporting of such cases are crucial to improving diagnostic recognition, refining prognostic assessment, and optimizing therapeutic decision-making in MM patients with extramedullary cutaneous manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.